Gabriella Moretti

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Pierfranco Conté, Antonio Frassoldati, Giancarlo Bisagni et al. · Annals of Oncology · 2018 · 152 citations · Full text

Central Nervous System Metastases in HER-2–Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

Stefania Gori, S Rimondini, Verena De Angelis et al. · The Oncologist · 2007 · 145 citations · Full text

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni et al. · Annals of Oncology · 2019 · 93 citations · Full text

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni et al. · The Lancet Oncology · 2021 · 82 citations

Breast Oncology, Oncology, Postmenopausal Patients +9